Ruth M ORegan
Overview
Explore the profile of Ruth M ORegan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
2883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jones V, Yin H, Yuan Y, Wang Y, Li S, Aljaber D, et al.
Sci Rep
. 2025 Feb;
15(1):7220.
PMID: 40021703
Despite endocrine therapy (ET), approximately 20-40% of Stage I-III estrogen receptor-positive breast cancer (ER + BC) patients experience recurrence. Recurrence while on ET is indicative of ET resistance. This study...
2.
Tonetti D, Osipo C, ORegan R
Cancer
. 2024 Dec;
131(1):e35643.
PMID: 39621332
No abstract available.
3.
Bakhtiar H, Sharifi M, Helzer K, Shi Y, Bootsma M, Shang T, et al.
NPJ Precis Oncol
. 2024 Oct;
8(1):220.
PMID: 39358429
In preclinical studies, p53 loss of function impacts chemotherapy response, but this has not been consistently validated clinically. We trained a TP53-loss phenocopy gene expression signature from pan-cancer clinical samples...
4.
ORegan R, Zhang Y, Fleming G, Francis P, Kammler R, Viale G, et al.
JAMA Oncol
. 2024 Aug;
10(10):1379-1389.
PMID: 39145953
Importance: Adjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor-positive (HR+) breast cancer but adds adverse effects. A genomic biomarker for selecting...
5.
6.
Vigolo M, Urech C, Lamy S, Monticone G, Zabaleta J, Hossain F, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568775
Background: The efficacy of CB-103 was evaluated in preclinical models of both ER+ and TNBC. Furthermore, the therapeutic efficacy of combining CB-103 with fulvestrant in ER+ BC and paclitaxel in...
7.
Hall W, ODell N, Gordon S, Ogden S, McLetchie A, ORegan R
Acad Med
. 2023 Aug;
98(11):1235.
PMID: 37556824
No abstract available.
8.
Sharifi M, ORegan R, Wisinski K
Clin Breast Cancer
. 2023 Jul;
23(8):813-824.
PMID: 37419745
Triple negative breast cancer (TNBC) is characterized by high rates of disease recurrence after definitive therapy, and median survival of less than 18 months in the metastatic setting. Systemic therapy...
9.
Meisel J, Harrington A, Whaley N, Vitek W, ORegan R
Cancer
. 2022 Nov;
129(2):171-174.
PMID: 36345655
No abstract available.
10.
Kharel Z, Nemer O, Xi W, Upadhayaya B, Falkson C, ORegan R, et al.
Breast Dis
. 2022 Sep;
41(1):363.
PMID: 36057835
No abstract available.